• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.
    All News #Library
    Biotech

    Tango Therapeutics Reports 2025 Financial & Business Updates

    GLOBENEWSWIRE

    Tango Therapeutics Joins Guggenheim Biotech Summit 2026

    GLOBENEWSWIRE

    Tango Therapeutics Names Malte Peters CEO, Replacing Barbara

    GLOBENEWSWIRE

    Tango Therapeutics Unveils Q3 2025 Financials & Business Update

    GLOBENEWSWIRE

    Tango Therapeutics Reveals Encouraging Phase 1/2 Data with TNG462

    GLOBENEWSWIRE

    Tango Therapeutics Announces $225 Million Financing

    GLOBENEWSWIRE

    Tango Therapeutics To Unveil TNG260 Clinical Data at SITC 2025

    GLOBENEWSWIRE

    Tango Therapeutics to Attend 2025 Cantor Global Health Conference

    GLOBENEWSWIRE

    Tango Therapeutics Reports Q2 2025 Financials and Business

    GLOBENEWSWIRE

    Tango Therapeutics to Report Q2 2025 Financial Results

    GLOBENEWSWIRE

    Tango Doses First Patient In Ph1/2 Trial Of TNG456

    GLOBENEWSWIRE

    Tango dances away from preclinical work to extend cash runway

    FIERCE BIOTECH

    Tango Therapeutics Reports Q1 2025 Financial Results & Business

    GLOBENEWSWIRE

    Tango Therapeutics to Report Q1 2025 Results on May 12, 2025

    GLOBENEWSWIRE

    Tango Therapeutics Reports Q4 and Full Year 2024 Results

    GLOBENEWSWIRE

    Tango Therapeutics To Present At Three Investment Conferences

    GLOBENEWSWIRE

    Tango Therapeutics to Present at Guggenheim Biotech Conference

    GLOBENEWSWIRE

    Tango Announces Inducement Grants Under Nasdaq Rule 5635(c)(4)

    BUSINESSWIRE

    Tango to Present at Piper Sandler 36th Annual Healthcare Conference

    BUSINESSWIRE

    Tango Therapeutics Reports Positive TNG462 Data & PRMT5 Update

    BUSINESSWIRE

    Tango Therapeutics Reports Q3 2024 Results & Business Highlights

    BUSINESSWIRE

    Tango Therapeutics to Participate in Upcoming Investor Conferences

    BUSINESSWIRE

    Tango Therapeutics Reports Q2 2024 Results And Business Highlights

    BUSINESSWIRE

    Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.